Indacaterol/glycopyrronium versus salmeterol/fluticasone in the prevention of clinically important deterioration in COPD: results from the FLAME study.

Respir Res · 2018 · PMC6011394 · PMID 29925383

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Subgroup analysis Among the subgroups evaluated, IND/GLY significantly reduced the risk of CID versus SFC in all subgroups; in the groups of patients with baseline eosinophil count ≥300 cells/μL and those with very severe COPD, numerical reductions in the risk were observed, that did not reach statistical significance (Fig. 3 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.